Aminosalicylate use by men with inflammatory bowel disease (IBD) is associated with a decreased risk of prostate cancer (PCa), investigators reported online in the Journal of Gastroenterology.

J. Clair Wilson, PhD, of the University of Basel in Switzerland, and colleagues identified 1,077 cancers among 19,647 patients with a first-time diagnosis of IBD and a randomly matched group of an equal number of patients without IBD. The researchers observed no association between IBD and overall cancer risk, but aminosalicylate use by IBD patients was associated with adjusted 68% decreased risk of PCa and 28% decreased risk of all cancers.

Continue Reading